FURTHER EXPERIMENTS WITH THE INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS.

Goodner K. · 1928

Read FURTHER EXPERIMENTS WITH THE INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS. by Goodner K. (1928) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2131476.txt.

Introduction

Kenneth Goodner continued experiments in 1928 on pneumococcus infection placed in the skin of rabbits. Type I pneumococci set in the skin give a disease that mirrors human lobar pneumonia in many points. This report adds further proof of that likeness and turns to treatment with antiserum, asking how dose and timing shape the cure.

The amount of antiserum needed for success rose as the disease progressed, and it rose in a definite mathematical pattern. Goodner reads that pattern as the steady buildup of some toxic or opposing substance. Seven lots of serum were tested in rabbits: their healing value did not match their mouse-protective value. He suggests the rabbit test as a fair, simple standard for ranking such sera.

Catalog record

CREATORGoodner K.
YEAR1928
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2131476

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

FURTHER EXPERIMENTS WITH THE INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS By Kenneth Goodner Published in: The Journal of Experimental Medicine DOI: 10.1084/jem.48.3.413 ABSTRACT 1. The continuation of our experiments with intradermal Type I pneumococcus infection in rabbits has furnished further evidence of the marked analogies between this condition and that of human lobar pneumonia. 2. It has been found that the amount of antiserum necessary for successful therapy increases as the disease progresses, and that this progression has a definite mathematical character. Such a condition, it seems, can only be caused by a progressive accumulation of some toxic or antagonistic substance, the exact nature of which is not known. 3. Various lots of antipneumococcus sera have been tested for their therapeutic properties. The results from seven such sera show that this therapeutic value does not parallel the mouse-protective value. It is suggested that the rabbit technic may prove useful for the routine comparison and standardization of antipneumococcus sera since it represents a simple method for determining that property for which the serum is to be utilized. 4. The effect of non-specific therapy in this condition has been determined to be a transient disappearance from the blood stream of circulating organisms. This result was obtained with such heterologous materials as normal horse serum and typhoid vaccine but not with the homologous normal rabbit serum. 5. Rabbits recovering from the intradermal disease without treatment or with such inadequate treatment that the disease runs its normal course, were shown to have a definite though not permanent immunity. Cases in which the disease had been arrested at 24 hours by effective therapy with heterologous immune serum showed no immunity after the early disappearance of the passively administered elements. Cases which were brought to early recovery with immune homologous serum did show a definite immunity comparable to that which was developed in other animals as the result of an untreated course of the disease. 6. The immunity conferred by single and multiple vaccination is reported. The possibility of the application of such methods in the pneumonias of man is discussed and a method for such an application is suggested. FURTHER EXPERIMENTS WITH THE INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS. BY KENNETH GOODNER. (From tke Departmentof Bacteriologyand Immunology of Harvard University MedicalSchool,Boston.) (Receivedfor publication,June 8, 1928.) In a previous communication (1) we have described the character- istic symptom-complex brought about by infecting rabbits intrader- really with Type I pneumococci. The following paper is a continua- tion of that report. I. Specific Serum Therapy. Since we believe that the rabbit experiment as described in our first paper promises a method of determining the therapeutic potency of specific antipneumococcic serum more satisfactorily than the now prevalent mouse protection technic we have given considerable atten- tion to the effects of serum administration on the course of the pneu- mococcus infection of rabbits, both in regard to the local and general phenomena. The following points have already been established: 1. That animals recover promptly after the intravenous adminis- tration of large amounts of antipneumococcic serum. 2. That there are four important features of this induced recovery, as follow: (a) the immediate and permanent disappearance of organ- isms from the circulating blood; (b) a drop in temperature to normal levels within 24 hours; (c) the disappearance of organisms from the local lesion in the course of 4 to 20 hours; (d) loss of inflBmmatory color of the local lesion within 24 hours, usually accompanied by epidermal desquamation. 3. That for a given serum at a given stage of the disease there may be established a minimal effective dosage (~r.E.D.) such that larger 413 414 INTRADERMAL PNETJMOCOCCTJS INFECTION amounts give no added therapeutic value and smaller amounts are insufficient to bring about recovery. Minimal Effective Dosage at Various Stages of the Disease.--It is a common clinical observation that the amount of serum which might be used effectively on the 1st or 2nd day of lobar pneumonia is insuffi- cient if given at a later time. Some clinicians have even stated that after the infection has progressed beyond a certain point no amount of serum will save. The question of a quantitative element has been studied in the experimental "dermal pneumonia" of the rabbit by determining the minimal effective dose of a given serum for each of three stages of the disease. It is necessary to stress again the sharpness of the end-point in determinations of the effectiveness of therapeutic sera. The re- sults of such an experiment are shown in Fig. 1. This experiment shows that the amount of serum necessary for effective therapy increases very rapidly as the disease progresses and emphasizes the importance of early treatment. Even the time occu- pied in the ordinary typing process would greatly lessen or entirely eliminate the chances of successful therapy. For this particular serum, if one assumed a definite relationship between therapeutic dose and body weight of the animal and trans- ferred these proportions to man, the results would be as follow: In the standard rabbit (1500 gin.) we have found it necessary to use serum to the amount of 0.23 per cent of body weight at 24 hours, 0.47 per cent at 48 hours, and approximately 0.67 per cent at 72 hours. This would indicate that in a man of 70 kilos it would be necessary to use 150 cc. of this serum at 24 hours, 325 cc. at 48 hours, and approxi- mately 475 cc. at 72 hours. In the experimental rabbit condition it is not essential that the minimal effective level be exceeded at a single injection but if multiple injections are used these must not be too far apart and the total quan- tity must exceed the minimal effective amount for that period. Un- less this effective level is exceeded at a given time absolutely no beneficial result has been obtained. Bloomfield (2) advances the opinion that in lobar pneumonia the usefulness of serum depends upon the presence and seriousness of the bacteriemia. The rabbits which we have studied have shown some KENNETtt GOODNER 415 variation in the severity of the bacteriemia at the time of treatment but the minimal effective dosage of the serum appears to be a fixed quantity for a given period and this does not vary with the severity of the bacteriemia. If such a correlation did exist it might be antici- pated that ten times as much serum would be necessary at 48 hours *~ I *P" |t tJ tJ ~ ? E g = 3 .u J *. Po~It~v~ ~rolxeuTir.~csult , / V' ) / ,/ / / / / / / - ) / FIo. 1. Determinations of the minimal effective dosage of Antipneumococcic Serum P 315 at various stages of the disease. The diagonal line represents the suggested effective level of therapy. as was necessary at 24 hours, for the number of bacteria per cc. of blood has often increased by a multiple of 10 or even of 100. The contour of the suggested boundary curve, shown by the broken line in Fig. 1, suggests that there is a progressive rise in some element which unites quantitatively with the antiserum or quantitatively 416 INTRADERM.AL PNEU~OCOCCUS INFECTIO1V antagonizes it. Proponents of the pneumonia toxin

Read the complete text